Hepavue has developed a proprietary virtual liver biopsy that utilizes molecular tracers and AI-based medical imaging technology for the early detection of progressive liver diseases. This non-invasive method addresses the limitations of traditional needle biopsies, which are costly, painful, and carry significant risks, by providing a safer and more accessible diagnostic alternative.
Funding
$113.4K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Over two billion people globally have asymptomatic chronic liver disease, which often progresses silently. Traditional needle biopsies for diagnosis are invasive, expensive, and carry risks, making them unsuitable for mass screening and early detection. Consequently, a significant percentage of patients are diagnosed only at terminal stages of liver disease.
Solution
Hepavue offers a non-invasive virtual liver biopsy using molecular tracers and AI-based medical imaging to detect progressive liver diseases early. This method provides a safer, more affordable, and accessible alternative to traditional needle biopsies, enabling timely management strategies. Hepavue's technology allows for the early detection of liver disease, potentially preventing avoidable cases of liver cancer, transplantations, and deaths. The platform also facilitates personalized assessment of therapeutic responses, ensuring tailored and effective care for patients with liver conditions.
Target Audience
The primary target audience includes hepatologists, gastroenterologists, and other medical professionals involved in diagnosing and managing liver diseases, as well as patients at risk of or suspected to have liver conditions.
Features
- Combines molecular tracers with AI-driven medical imaging for enhanced diagnostic accuracy.
- Provides early detection of progressive liver diseases, enabling proactive intervention.
- Offers a non-invasive alternative to traditional needle biopsies, reducing patient risk and discomfort.
- Facilitates personalized assessment of therapeutic responses for tailored treatment plans.
- Aims for rapid elimination of tracers through kidney filtration.